Spravato denied due to quantity / dose limits by Aetna?

Aetna's specific coverage criteria for spravato are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna May Deny Spravato for Exceeding Quantity Limits

Aetna's quantity-limit denial for esketamine nasal spray (Spravato) means the plan will cover a defined number of administrations per period, and the requested quantity exceeds that limit. Quantity limits for Spravato are common because the FDA-approved prescribing label itself distinguishes between an induction phase and a maintenance phase with different recommended administration frequencies. Aetna's quantity limits are typically calibrated to the induction-phase frequency, so requests to continue at that frequency into what the prescriber considers a continuation or maintenance phase — or requests for more frequent dosing based on individual clinical need — can trigger this denial.

## Federal Appeal Framework

• Internal appeal (ACA §2719 / ERISA §503): File within the deadline stated on your denial notice. Aetna must respond within 30 days (prospective) or 60 days (post-service).
• Quantity-limit exception: Some plans process these as a formulary exception rather than a full appeal. Ask Aetna whether a quantity-limit exception process applies and submit the prescriber's clinical rationale through that channel simultaneously.
• External review: After an adverse internal decision, IRO external review is available, generally within four months of the final denial.
• Expedited track: Request 72-hour expedited review if clinical urgency supports it.

## Documentation to Gather

1. Prescriber's clinical rationale: A letter from the treating psychiatrist explaining why the requested number of administrations per period is medically necessary for this patient — including the current phase of treatment, the patient's response trajectory, and why the standard quantity limit is clinically insufficient. 2. FDA label reference: Reference the FDA-approved prescribing information (without citing specific numeric doses) to show the requested frequency is consistent with recognized clinical use and that the prescribing label contemplates individualized frequency adjustments. 3. Treatment-response documentation: Chart notes showing the patient's clinical response over time, including any periods of symptom worsening when administration frequency was reduced, supporting the prescriber's rationale for the requested quantity. 4. Diagnosis and severity records: Current psychiatric documentation of diagnosis, severity, and functional status. 5. Aetna's policy review: Obtain Aetna's current published medical policy for Spravato, identify the specific quantity-limit criterion being applied, and address it directly.

## Criteria-Mapping Structure

In your appeal, lead with the FDA-approved prescribing label's description of individualized dosing flexibility, then present the patient-specific clinical evidence that justifies the requested quantity. Attach the prescriber letter, relevant chart excerpts, and a direct response to each quantity-limit criterion in Aetna's policy. Quantity-limit appeals succeed most often when the prescriber's letter connects the patient's documented clinical course to the reason a higher quantity is medically necessary — not just preferred.